Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials

Table 2 Patients` characteristics at first diagnosis

Variable	Overall cohort		RVd (six 21-day cycles)		Isatuximab –RVd (six 21-day cycles)		RVd (four 21-day cycles)		elotuzumab-RVd (four 21-day cycles)		p value
Variable	n	%	n	%	n	%	n	%	n	%	p value
Patient number	179	100	44	100	35	100	51	100	49	100	/
Gender											0.808
Male	114	62	30	68	23	66	30	59	31	63
Female	65	38	14	32	12	34	21	41	18	37
FIRST DIAGNOSIS											/
Diagnosis
MM	178	99	44	100	35	100	51	100	48	98
Plasma cell leukaemia	1	1	0	0	0	0	0	0	1	2
Mean age at diagnosis, years (SD)	58	8	58	9	58	7	56	9	58	7	0.615
Heavy chain type											0.523^a
IgG	116	65	25	57	25	71	32	63	34	69
IgA	32	18	11	25	5	14	6	12	10	20
IgM	3	2	1	2	1	3	1	2	0	0
IgD	0	0	0	0	0	0	0	0	0	0
Double gammopathy	2	1	1	2	0	0	1	2	0	0
Light chain only	26	15	6	14	4	11	11	22	5	10
Non-secretory	0	0	0	0	0	0	0	0	0	0
Light chain type											0.117^b
Lambda	64	36	11	25	18	51	15	29	20	41
Kappa	114	64	32	73	17	49	36	71	29	59
Double gammopathy	1	1	1	2	0	0	0	0	0	0
Non-secretory	0	0	0	0	0	0	0	0	0	0
ISS stage											0.139
I	97	54	25	57	14	40	28	55	30	61
II	41	23	7	16	14	40	11	22	9	18
III	36	20	12	27	7	20	9	18	8	16
NA	5	3	0	0	0	0	3	6	2	4
Cytogenetic profile											0.793
High-risk	51	28	11	25	9	26	17	33	14	29
Standard risk	114	64	29	66	24	69	30	59	31	63
NA	14	8	4	9	2	6	4	8	4	8

Ig Immunoglobulin, ISS International Staging System, MM Multiple myeloma, NA Not available, PBSC Peripheral blood stem cells, SD Standard deviation
^aIgG versus IgA,IgD,IgM, Double Gammopathy versus Light chain only
^bLambda versus Kappa

ISSN: 1471-2407